Only 15 percent of the electrode-bearing threads implanted in the brain of Neuralink’s first human brain-chip patient continue to work properly, according to a report from The Wall Street Journal.
The adjustments were effective enough to regain and then exceed performance on at least one metric—the bits-per-second (BPS) rate used to measure how quickly and accurately a patient with an implant can control a computer cursor.
He initially asked if Neuralink would perform another surgery to fix or replace the implant, but the company declined, telling him it wanted to wait for more information.
The Journal’s report adds more detail about the thread retraction as Neuralink gears up to surgically implant its chip into a second trial participant.
According to the report, the company hopes to perform the second surgery sometime in June and has gained a green light to do so from the Food and Drug Administration, which oversees clinical trials.
Neuralink, owned by controversial billionaire Elon Musk, believes it can prevent thread movement in the next patient by simply implanting the fine wires deeper into brain tissue.
The original article contains 481 words, the summary contains 179 words. Saved 63%. I’m a bot and I’m open source!
This is the best summary I could come up with:
Only 15 percent of the electrode-bearing threads implanted in the brain of Neuralink’s first human brain-chip patient continue to work properly, according to a report from The Wall Street Journal.
The adjustments were effective enough to regain and then exceed performance on at least one metric—the bits-per-second (BPS) rate used to measure how quickly and accurately a patient with an implant can control a computer cursor.
He initially asked if Neuralink would perform another surgery to fix or replace the implant, but the company declined, telling him it wanted to wait for more information.
The Journal’s report adds more detail about the thread retraction as Neuralink gears up to surgically implant its chip into a second trial participant.
According to the report, the company hopes to perform the second surgery sometime in June and has gained a green light to do so from the Food and Drug Administration, which oversees clinical trials.
Neuralink, owned by controversial billionaire Elon Musk, believes it can prevent thread movement in the next patient by simply implanting the fine wires deeper into brain tissue.
The original article contains 481 words, the summary contains 179 words. Saved 63%. I’m a bot and I’m open source!